Pharmaceuticals
IASO Biotherapeutics and Innovent Biologics Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting
SAN JOSE and SAN FRANCISCO and NANJING, China, Dec. 12, 2021 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company focused on discovering, developing, and manufacturing innovative medicines and Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-cla...
2021-12-13 12:14
2761
Phase 3 Data Demonstrate TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
TIBSOVO in combination with azacitidine compared to placebo plus azacitidine also demonstrated significant improvements in complete remission rate, complete remission and complete remission with partial hematologic recovery rate and objective response rate Safety profile was favorable and consis...
2021-12-13 09:03
3607
Innovent and IASO Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting
SAN FRANCISCO, U.S. and SUZHOU, China, Dec. 13, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other ma...
2021-12-13 08:00
4269
StemiRNA Therapeutics appoints Dr. Jack Hu as Chief Financial Officer
SHANGHAI and BOSTON, Dec. 12, 2021 /PRNewswire/ -- StemiRNA, a leader in research and development of mRNA therapeutics, welcomes Dr.Jack Hu as Chief Financial Officer. Dr. Hu brings nearly two decades of experience in healthcare investment research, financial management and corporate strategy. Dr...
2021-12-13 07:00
2414
Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant
DURHAM, N.C. and BEIJING, Dec. 12, 2021 /PRNewswire/ -- Brii Biosciences
2021-12-12 18:50
5142
Phase 3 Data Show That TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
* TIBSOVO in combination with azacitidine compared to placebo plus azacitidine also demonstrated significant improvement in complete remission rate, complete remission and complete remission with partial hematologic recovery rate and objective response rate * Safety profile was favorable and ...
2021-12-12 09:00
6848
Qiming's Portfolio Company CANbridge Pharmaceuticals Lists on Main Board of HKEx
SHANGHAI, Dec. 10, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company CANbridge Pharmaceuticals (SEHK: 1228), a leadingChina-based global rare disease-focused biopharmaceutical company, today listed on the main board of Hong Kong Stock Exchange. The issue price isHK$ 12.18 per share,...
2021-12-10 15:15
5380
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
CASTRES, France, Dec. 10, 2021 /PRNewswire/ -- Today, the final findings of the CONTROL study1 were presented at the 2021 San Antonio Breast Cancer Symposium (SABCS). Results suggest that providing a prophylactic anti-diarrhoea medical treatment or applying a dose escalation schedule of neratinib...
2021-12-10 15:11
3160
Research shows Lianhua Qingwen capsules conferred preventive effects on those exposed to COVID-19
SHIJIAZHUANG, China, Dec. 10, 2021 /PRNewswire/ -- "Lianhua Qingwen capsules conferred preventive effects on those exposed to COVID-19", claimed an article titled "Efficacy and Safety of Lianhuaqingwen Capsules for the Prevention of Coronavirus Disease 2019: A Prospective Open-Label Controlled Tr...
2021-12-10 12:49
4282
Bora Pharmaceuticals collaborates with Taishin Holdings to launch CDMO investment and M&A plan
TAIPEI, Taiwan, Dec. 8, 2021 /PRNewswire/ -- Bobby Sheng, chairman of Bora Pharmaceuticals (6472.TWO), today announced a partnership with Taishin Healthcare Limited Partnership at the 2021 Biotech Investor Forum, whereby the two parties will jointly invest up toNT$3 billion (approx. US$108 millio...
2021-12-10 12:17
4205
I-Mab to Hold Investor Call to Present In-depth Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma
SHANGHAI and GAITHERSBURG, Md., Dec. 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors at8:00 a.m. EST o...
2021-12-09 21:00
2343
Seegene Rapidly Introduces New PCR Test that Identifies the Omicron Variant, its Stealth Version, and all VOCs in a single tube
SEOUL, South Korea, Dec. 9, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today unveiled another series of diagnostic test that detects the ever-changing COVID-19 variant landscape. The Novaplex™ SARS-CoV-2 Variants VII assay addresses Omicron...
2021-12-09 20:18
2825
Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients
HANGZHOU, China and SAN FRANCISCO, Dec. 9, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the completion of patient enrollment in its Phase 2 clin...
2021-12-09 20:00
3293
Another clean interim safety review of RhoVac's clinical phase IIb study in prostate cancer
HELSINKI, Dec. 9, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today onDecember 9th, 2021, that its Data & Safety Monitoring Committee (DSMC) has conducted a planned interim safety review of its clinical phase IIb trial in prostate cancer, known as ...
2021-12-09 16:58
1628
Posters Highlighting clinical data of KN026 presented at SABCS 2021
SUZHOU, China, Dec. 9, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced that two posters highlighting data from two clinicalstudies of the anti-HER2 bispecific antibody KN026 were presented at the 44th San...
2021-12-09 12:20
2937
Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021
- Trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs. standard of care (SoC) endocrine therapy in overall population and estrogen receptor mutation (mESR1) population - In the overall p...
2021-12-09 08:38
3496
Servatus raises $7.5 million to advance autoimmune therapies with its microbial biotherapeutics clinical programs
* Servatus has raised $7.5 million in an oversubscribed capital raise, with strong support from sophisticated shareholders * Funds raised will underpin Servatus' live microbial and engineered protein biotherapeutics drug development * Two Phase 1/2 clinical trials to launch shortly in Queens...
2021-12-09 07:35
3607
Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China
The approval marks the first locally-discovered and approved SARS-CoV-2 target-specific treatment inChina, through a randomized, double-blind and placebo-controlled trial Brii Bio is also seeking U.S. FDA Emergency Use Authorization for the amubarvimab/romlusevimab combination DURHAM, N.C. and ...
2021-12-09 06:10
4331
I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease
SHANGHAI and GAITHERSBURG, Md., Dec. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient had been dosed in the I-Mab and Nh...
2021-12-08 21:00
3742
China's Largest Commercial GMP Plasmid Manufacturing Facility is Put into Operation, GenScript ProBio Expanding Manufacturing Capacity Again
NANJING, China, Dec. 8, 2021 /PRNewswire/ -- On December 7th, the "Opening Ceremony of GenScript ProBio Plasmid Commercial GMP Manufacturing facility and Open Day" was rounded off. GenScript ProBio at the opening ceremony announced thatthe largest commercial GMP plasmid manufacturing facility in ...
2021-12-08 18:22
3752
Week's Top Stories
Most Reposted
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
[Picked up by 309 media titles]
2026-07-30 10:45
J.P. Morgan Private Bank Earns Record 10 Accolades at The Asset Triple A Private Capital Awards 2026
[Picked up by 294 media titles]
2026-07-30 15:00KC Global Media announces new travel series "AXN Ultimate Challenge: Sarawak"
[Picked up by 291 media titles]
2026-07-30 09:12
Articura Launches a New Chapter for Sovereign Healthcare AI in Indonesia
[Picked up by 290 media titles]
2026-07-27 19:02
ADA acquires Algonomy, strengthening its intelligent growth platform for a fully agentic experience
[Picked up by 290 media titles]
2026-07-30 15:30
